Explore a groundbreaking conference talk from the AAAS Annual Meeting that delves into the development of an mRNA vaccine for treating autoimmune diseases in mice. Learn about the innovative approach used by Christina Krienke and colleagues to create a vaccine that delays the onset and reduces the severity of multiple sclerosis-like conditions. Discover how this targeted vaccine restores the body's tolerance to its own proteins, suppressing immune overreactivity without compromising overall immune function. Gain insights into the vaccine's composition, its mechanism of action, and its potential for creating personalized autoimmune disease treatments. Examine the experimental results in mice with autoimmune encephalomyelitis and understand the implications for human multiple sclerosis treatment. The 37-minute presentation covers key topics including regulatory T cells, the principles behind the vaccine, and future applications of mRNA vaccine technology in areas such as universal flu vaccines, cancer treatment, and HIV prevention. Read more